Symbiotec Pharmalab IPO
ListedIPOListing at: BSE, NSE • Sector: Pending Review • 385/2,Pigdamber, Rau,Mhow,Indore, Madhya Pradesh, 453331
Disclaimer: GMP values change dynamically. This data is strictly for educational purposes only and not an investment advice.
Symbiotec Pharmalab IPO GMP History
Genuine daily snapshots retained by the WeeStox backendDisclaimer: GMP values change dynamically. This data is strictly for educational purposes only and not an investment advice.
| GMP date | IPO price | GMP | Premium | Est. profit / lot | Subscription | Movement |
|---|---|---|---|---|---|---|
| 05 Sept 2026 | ₹988 | +₹185 | 18.72% | +₹2,775 | 75.08x | Flat |
| 04 Sept 2026 | ₹988 | +₹185 | 18.72% | +₹2,775 | 75.08x | Flat |
| 03 Sept 2026 | ₹988 | +₹185 | 18.72% | +₹2,775 | 75.08x | Flat |
| 02 Sept 2026 | ₹988 | +₹185 | 18.72% | +₹2,775 | 75.08x | Flat |
| 01 Sept 2026 | ₹988 | +₹185 | 18.72% | +₹2,775 | 75.08x | ↓ Down |
| 29 Aug 2026 | ₹988 | +₹250 | 25.30% | +₹3,750 | 75.08x | ↓ Down |
| 25 Aug 2026 | ₹988 | +₹352 | 35.63% | +₹5,280 | 1.95x | Flat |
Explore the complete GMP movement
Open the chart and all available daily records.
Symbiotec Pharmalab IPO Details
| IPO Date | 23 Aug 2026 to 26 Aug 2026 |
| Listing At | BSE, NSE |
| Face Value | ₹2 per share |
| Price Band | ₹938 - ₹988 |
| Lot Size | 15 Shares |
| Total Issue Size | ₹1757.00 Cr(₹1,255.57 Cr) |
| Fresh Issue | 15.21L shares (₹150.27 Cr) |
| Offer for Sale (OFS) | ₹1606.72 Cr (approx 2.74 Cr shares) |
| Issue Type | Book Built Issue IPO |
Symbiotec Pharmalab IPO Timetable
| IPO Open Date | 23 Aug 2026 |
| IPO Close Date | 26 Aug 2026 |
| Basis of Allotment | 27 Aug 2026 |
| Initiation of Refunds | 30 Aug 2026 |
| Credit of Shares to Demat | 30 Aug 2026 |
| Listing Date | 31 Aug 2026 |
| Cut-off time for UPI Mandate | 5 PM on 26 Aug 2026 |
| Employee Discount | ₹20.00/share (Up to 52,083 shares) |
Symbiotec Pharmalab IPO Reservation
| Category | Reservation | Shares Offered |
|---|---|---|
| Anchor Shares Offered | 29.94% | 53,25,909 |
| QIB Shares Offered | 19.96% | 35,50,608 |
| HNI Shares Offered | 14.97% | 26,62,955 |
| Retail Shares Offered | 34.93% | 62,13,562 |
| Employee Shares Offered | 0.19% | 33,408 |
| Total Shares Offered | 100.00% | 1,77,86,442 |
Symbiotec Pharmalab Anchor Details
| Anchor Bid Date | 20 Aug 2026 |
| Anchor Shares Offered | 53,25,909 Shares |
| Total Anchor Portion | ₹526.2 Cr |
| Lock-in 50% End Date | 25 Sept 2026 (30 Days) |
| Lock-in Rem. 50% Date | 24 Nov 2026 (90 Days) |
Symbiotec Pharmalab IPO Lot Size
| Application | Lots | Shares | Amount (Cut-off) | Reserved Applications |
|---|---|---|---|---|
| Retail | 1 Lot | 15 Shares | ₹14,820 | 4,14,237 |
| sHNI | 14 Lots | 210 Shares | ₹2,07,480 | 4,277 |
| bHNI | 68 Lots | 1020 Shares | ₹10,07,760 | 8,454 |
Symbiotec Pharmalab Promoter Holding
| Pre-Issue Holding | Disclosed in RHP |
| Post-Issue Holding | To be calculated |
Symbiotec Pharmalab IPO Broker Consensus & Reviews
Institutional and brokerage house recommendations with verified review reports| Broker / Research Firm | Recommendation | Research Report |
|---|---|---|
| Nirmal Bang | Apply | View Review |
| Adroit Financial Services Private Limited | Apply | View Review |
| Anand Rathi Advisors Ltd. | Apply | View Review |
| Angel One | Apply | View Review |
| SBICAP Securities Limited | Apply | View Review |
| BP Equities (BP Wealth) | Apply | View Review |
| Ventura Securities Limited | Apply | View Review |
| Kantilal Chhaganlal Securities Pvt Ltd | Apply | View Review |
| Swastika Investmart Ltd | Apply | View Review |
| Marwadi Shares and Finance Ltd | May Apply | View Review |
Symbiotec Pharmalab IPO Live Subscription Status
Bidding demand breakdown by shares, institutional demand in ₹ Cr, applications & HNI funding cost| Investor Category | Shares Offered | Shares Bidded | Subscription Times |
|---|---|---|---|
| QIBs | 35,50,608 | 64,33,59,195 | 181.20x |
| HNIs | 26,62,955 | 20,65,35,120 | 77.56x |
| ↳ HNIs 10+ | 17,75,303 | 15,50,46,495 | 87.34x |
| ↳ HNIs 2+ | 8,87,652 | 5,14,88,625 | 58.01x |
| Retail | 62,13,562 | 8,48,10,630 | 13.65x |
| Employees | 33,408 | 5,45,055 | 16.32x |
| Total | 1,24,60,533 | 93,52,50,000 | 75.06x |
Symbiotec Pharmalab Limited Financial Information (Restated Consolidated in ₹ Crores)
| Period Ended | Assets | Total Income | Profit After Tax | EBITDA | Net Worth | Total Borrowing |
|---|---|---|---|---|---|---|
| 30 Mar 2026 | ₹1780.79 Cr | ₹872.26 Cr | ₹109.90 Cr | ₹231.97 Cr | ₹1158.64 Cr | ₹387.91 Cr |
| 30 Mar 2025 | ₹1579.65 Cr | ₹755.98 Cr | ₹96.79 Cr | ₹206.11 Cr | ₹821.15 Cr | ₹540.92 Cr |
| 30 Mar 2024 | ₹1294.79 Cr | ₹723.33 Cr | ₹100.06 Cr | ₹177.04 Cr | ₹720.68 Cr | ₹247.21 Cr |
Symbiotec Pharmalab Key Valuation & Financial KPIs
Symbiotec Pharmalab IPO Analysis
Review the company's key advantages and material business risks.
Strengths & Positives
Competitive advantages and operational merits
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has received approvals from the US FDA, EU-GMP, Ministry of Food and Drug Safety, Korea, and other global organizations.
Global leadership in corticosteroid and steroidal-hormone APIs: The company has established expertise and a leadership position in the manufacturing of corticosteroid and steroidal-hormone APIs. Its specialized capabilities support its presence in the global pharmaceutical ingredients market.
Long-standing customer relationships: Symbiotec Pharmalab has developed long-standing relationships with domestic and international customers. These relationships support its established market presence and recurring business opportunities.
Vertically integrated manufacturing platform: The company operates a fully invested, multi-scale and vertically integrated manufacturing platform. Its integrated operations are supported by sustainable practices and a clean regulatory track record.
Dependence on export markets: The company generates a significant portion of its revenue from customers outside India, which contributed 66.67%, 55.19%, 59.97%, and 52.76% of revenue from operations in the three months ended June 30, 2025 and Fiscals 2025, 2024, and 2023, respectively. Inability to effectively manage risks associated with international sales could adversely affect overseas revenue and financial performance. Dependence on Imported Raw Materials: The company procures a portion of its raw material requirements from countries including China and the United States. Any adverse developments in these countries or changes in the laws governing imports could disrupt the supply of raw materials and adversely affect the company's results of operations, financial condition, and cash flows.
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab IPO is a book build issue of ₹1,757.00 crores. The issue is a combination of fresh issue of 15.21 lakh shares aggregating to ₹150.27 crores and offer for sale of 1.63 crore shares aggregating to ₹1,606.72 crores.Symbiotec Pharmalab IPO bidding started from Aug 24, 2026 and ended on Aug 27, 2026. The allotment for Symbiotec Pharmalab IPO was finalized on Aug 28, 2026. The shares got listed on NSE and BSE on Sep 1, 2026.Symbiotec Pharmalab IPO is set final issue price at ₹988 per share. The lot size for an application is 15 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,820 (15 shares) (based on upper price).The issue includes a reservation of up to 33,407 shares for employees offered at a discount of ₹90.00 to the issue price.JM Financial Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.Refer to Symbiotec Pharmalab IPO RHP for detailed Information.
Shariah Compliance Screening (AAOIFI Standard 21)
Symbiotec Pharmalab IPO Documents & Reports
Official prospectus, reports and regulatory filings| Document Title | Authority / Host | Status | Action |
|---|---|---|---|
Red Herring Prospectus (RHP) Complete offer document filed with ROC & SEBI | SEBI / ROC | Available | View RHP |
Draft Red Herring Prospectus (DRHP) Initial regulatory draft submitted for public comments | SEBI Filings | Filed | View DRHP |
Anchor Investor Allocation Report Allotment list to institutional bidders | BSE / NSE Circular | Disclosed | Not Applicable |
IPO Allotment Status & Basis of Allotment Registrar query portal via PAN / Application No. | MUFG Intime India Pvt.Ltd. | Live Portal | Check Allotment |
Corporate Website & Investor Relations Official portal and financial reports | Issuer Portal | Active | Visit Portal |
Symbiotec Pharmalab IPO Registrar & Lead Managers
- JM Financial Ltd.
- Avendus Capital Pvt.Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt.Ltd.
385/2,Pigdamber, Rau,Mhow,Indore, Madhya Pradesh, 453331